Here are the 424B prospectus supplements from Teva Pharm Indus Ltd (TEVJF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is issuing new senior unsecured Euro- and U.S. dollar‑denominated notes through three Dutch finance subsidiaries, with all principal and interest unconditionally guaranteed by Teva. The notes have maturities in 2032, 2033, 2034, 2036 and 2037 and pay annual interest in euros and semi‑annual interest in U.S. dollars.
Teva expects to use the net proceeds, together with cash on hand, primarily to fund conditional redemptions of existing higher‑coupon debt, including all outstanding 6.750% Senior Notes due 2028, all 7.875% and 7.375% sustainability‑linked Senior Notes due 2029, up to $450 million of 4.750% sustainability‑linked Senior Notes due 2027 and up to €1.25 billion of 4.375% sustainability‑linked Senior Notes due 2030, plus related fees and expenses, with any remainder used for general corporate purposes and further debt repayment.
Teva reports 2025 net revenues of $17.26 billion, GAAP net income attributable to Teva of $1.41 billion and Adjusted EBITDA of $5.31 billion, with total assets of $40.75 billion and total equity of $7.91 billion as of December 31, 2025. As of June 30, 2026, cash and cash equivalents were $3.66 billion and total short‑term debt was $4.50 billion.